No Data
No Data
Adaptimmune Therapeutics: A Hold Rating Amid Strategic Shifts and Delayed Revenue Prospects
European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower
European equities traded in the US as American depositary receipts rose Friday morning, gaining 0.61% to 1,418.20 on the S&P Europe Select ADR Index. The index is poised to end the week lower. From co
Why Adaptimmune Therapeutics (ADAP) Stock Is Moving
Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) shares are trading higher by 15.8% to $1.17 during Friday's session after the company and Galapagos entered a clinical collaboration to license Adaptim
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersNovo Integrated Sciences (NASDAQ:NVOS) stock moved upwards by 69.6% to $0.77 during Friday's pre-market session. The company's market cap stands at $14.5 million. Adaptimmune Therapeutics (NASD
Why Zscaler Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Shares of Zscaler, Inc. (NASDAQ:ZS) rose sharply in today's pre-market trading after the company reported better-than-expected third-quarter earnings.Zscaler said third-quarter revenue increased 32% y
Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug
Galapagos (GLPG) and Adaptimmune Therapeutics (ADAP) have entered into a clinical collaboration deal to evaluate the safety and efficacy of Adaptimmune's uza-cel in head and neck cancer using Galapagos' decentralized cell manufacturing platform, the companies said late Thursday.
No Data